214 related articles for article (PubMed ID: 20619446)
1. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.
Ghosh S; Albitar L; LeBaron R; Welch WR; Samimi G; Birrer MJ; Berkowitz RS; Mok SC
Gynecol Oncol; 2010 Oct; 119(1):114-20. PubMed ID: 20619446
[TBL] [Abstract][Full Text] [Related]
2. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.
Yeung TL; Leung CS; Wong KK; Samimi G; Thompson MS; Liu J; Zaid TM; Ghosh S; Birrer MJ; Mok SC
Cancer Res; 2013 Aug; 73(16):5016-28. PubMed ID: 23824740
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
4. miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway.
Salem M; O'Brien JA; Bernaudo S; Shawer H; Ye G; Brkić J; Amleh A; Vanderhyden BC; Refky B; Yang BB; Krylov SN; Peng C
Cancer Res; 2018 Aug; 78(15):4175-4190. PubMed ID: 29748371
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
Siamakpour-Reihani S; Owzar K; Jiang C; Turner T; Deng Y; Bean SM; Horton JK; Berchuck A; Marks JR; Dewhirst MW; Alvarez Secord A
Gynecol Oncol; 2015 Oct; 139(1):23-9. PubMed ID: 26260910
[TBL] [Abstract][Full Text] [Related]
6. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Sluiter NR; de Cuba EM; Kwakman R; Meijerink WJ; Delis-van Diemen PM; Coupé VM; Beliën JA; Meijer GA; de Hingh IH; te Velde EA
Clin Exp Metastasis; 2016 Apr; 33(4):297-307. PubMed ID: 26873137
[TBL] [Abstract][Full Text] [Related]
7. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
8. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
9. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
11. Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression.
Crasta JA; Mishra S; Vallikad E
Int J Gynecol Pathol; 2011 Nov; 30(6):521-6. PubMed ID: 21979585
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density.
Liu Y; Yu L; Wang Y; Zhang Y; Wang Y; Zhang G
J Cancer Res Clin Oncol; 2012 Apr; 138(4):647-55. PubMed ID: 22228137
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
14. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.
Cheon DJ; Tong Y; Sim MS; Dering J; Berel D; Cui X; Lester J; Beach JA; Tighiouart M; Walts AE; Karlan BY; Orsulic S
Clin Cancer Res; 2014 Feb; 20(3):711-23. PubMed ID: 24218511
[TBL] [Abstract][Full Text] [Related]
15. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
[TBL] [Abstract][Full Text] [Related]
16. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
17. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J
Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Nuti M; Taube ET; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Br J Cancer; 2018 Aug; 119(3):330-338. PubMed ID: 29955134
[TBL] [Abstract][Full Text] [Related]
19. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
20. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.
Zaid TM; Yeung TL; Thompson MS; Leung CS; Harding T; Co NN; Schmandt RS; Kwan SY; Rodriguez-Aguay C; Lopez-Berestein G; Sood AK; Wong KK; Birrer MJ; Mok SC
Clin Cancer Res; 2013 Feb; 19(4):809-20. PubMed ID: 23344261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]